Volume 19, Number 3—March 2013
Research
Effects of Vaccine Program against Pandemic Influenza A(H1N1) Virus, United States, 2009–2010
Rebekah H. Borse1, Sundar S. Shrestha, Anthony E. Fiore, Charisma Y. Atkins, James A. Singleton, Carolyn Furlow, and Martin I. Meltzer
Table 8
Results of sensitivity analyses to estimate number of cases, hospitalizations, and deaths prevented by vaccination against influenza A(H1N1)pdm09 virus obtained with various vaccine effectiveness scenarios*
| Outcomes prevented | Base estimate of vaccine effectiveness (range)† | Lower vaccine effectiveness (range)‡ | Higher vaccine effectiveness (range)§ |
|---|---|---|---|
| Clinical cases | 1,029,157 (712,908–1,458,930) | 639,449 (442,971–907,688) | 1,418,678 (983,671–2,004,053) |
| Hospitalizations | 6,240 (3,923–10,393) | 3,857 (3,923–6,418) | 8,674 (3,923–14,461) |
| Deaths | 315 (201–520) | 193 (124–319) | 438 (279–723) |
*Data reflect calculations made for scenario 6, outcomes of assuming different vaccine effectiveness.
†Assumed 62% effectiveness for all groups except those >65 y, for whom 43% effectiveness was assumed.
‡Assumed 40% effectiveness for all groups except the elderly, for whom 20% effectiveness was assumed.
§Assumed 85% effectiveness for all groups except the elderly, for whom 55% effectiveness was assumed.
1Current affiliation: Merck & Co., Inc., Lansdale, Pennsylvania, USA.
Page created: February 12, 2013
Page updated: February 12, 2013
Page reviewed: February 12, 2013
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.